Triplet Therapy for Multiple Myeloma
Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.
Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.
Clinical Pearls
Triplet therapies are often a combination of a novel drug (an IMiD or proteasome inhibitor) with two other agents or an IMiD and proteasome inhibitor with steroids. McCarthy says that triplet therapy is becoming a part of the gold standard for upfront myeloma treatment.
- The current thinking is moving away from doublet therapy and towards triplet therapy for myeloma
- Common triplet therapy regimens include:
- lenalidomide + bortezomib + dexamethasone
- cyclophosphamide + lenalidomide + dexamethasone
- cyclophosphamide + bortezomib + dexamethasone
- Triplet therapy is becoming a part of the gold standard for upfront myeloma treatment
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
